ArticleDermatology and therapy2026
Treatment Patterns and Economic Burden in Moderate to Severe Chronic Hand Eczema in the USA: A Real-World Retrospective Claims Analysis.
Article in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAlthough Chronic Hand Eczema (CHE) is associated with substantial humanistic burden, treatment patterns and economic impact are poorly understood in the USA. Therefore, this study characterized real-world treatment patterns and economic burden among patients with moderate to severe CHE in the USA.
methodsUS claims data (01/2016-04/2024) were used to identify adults with moderate to severe CHE. Treatments were assessed post-diagnosis, with patients stratified into non-mutually exclusive cohorts on the basis of eczema/dermatitis-related treatment received. Eczema/dermatitis-related healthcare resource utilization and costs were descriptively reported while on treatment.
resultsIn total, 6295 patients with moderate to severe CHE were included (mean age: 48.2 years; 63.8% female; 76.6% commercially insured). Topical and systemic corticosteroid therapies were used by 81.3% and 86.2% of patients, respectively. Treatment patterns were heterogeneous; patients frequently transitioned between systemic, topical, and no treatment. Total eczema/dermatitis-related costs per-person-per-year increased with treatment intensity, to $21,682 among patients receiving monoclonal antibodies/oral Janus kinase inhibitors.
conclusionsSubstantial disease heterogeneity, extensive corticosteroid reliance, and steep increases in healthcare costs with treatment escalation were observed, underscoring an urgent need for CHE-specific therapies capable of providing durable control and reducing inappropriate resource use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.